...
首页> 外文期刊>Cancer Medicine >Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients
【24h】

Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients

机译:诺模图的开发和验证可预测IV期乳腺癌患者的总体生存

获取原文

摘要

Abstract This study aimed to develop a nomogram to predict the overall survival (OS) of stage IV breast cancer patients. We searched the National Cancer Database (NCDB) for stage IV breast cancer patients diagnosed between 2010 and 2013. Predictors of OS were identified and a nomogram was developed and validated using concordance index (C-index), calibration plots, and risk group stratifications. A total of 7199 patients from the NCDB were included in the study. With a median follow-up of 25.7 months, the 1-year and 3-year OS rates were 80.6% and 52.5%, respectively. Race, age, comorbidity status, T-stage, grade, ER/PR/Her2 status, the presence of lung/liver/brain metastasis, surgery, radiotherapy, and chemotherapy were significantly associated with OS. The developed nomogram had a C-index of 0.722 (95% CI 0.710?¢????0.734) and 0.725 (95% CI 0.713?¢????0.736) in the training and the validation cohorts, respectively. The predicted survival using the nomogram is well correlated with actual OS. The nomogram was able to stratify patients into different risk groups, among which the survival benefit of local therapy varied. We developed a nomogram to predict the overall survival of stage IV breast cancer patients. Prospectively designed studies with international collaborations are needed to further validate our nomogram.
机译:摘要这项研究旨在开发诺模图来预测IV期乳腺癌患者的总体生存期(OS)。我们在国家癌症数据库(NCDB)中搜索了2010年至2013年期间诊断出的IV期乳腺癌患者。确定了OS的预测因素,并使用一致性指数(C-index),校正图和风险组分层来开发并验证了列线图。该研究共纳入了来自NCDB的7199名患者。中位随访25.7个月,一年和三年OS发生率分别为80.6%和52.5%。种族,年龄,合并症,T期,等级,ER / PR / Her2状况,肺/肝/脑转移,手术,放疗和化疗与OS显着相关。在训练和验证队列中,展开的列线图的C指数分别为0.722(95%CI0.710≤0.734)和0.725(95%CI0.713≤0.736)。使用列线图预测的生存率与实际OS高度相关。诺模图能够将患者分为不同的风险组,其中局部治疗的生存获益各不相同。我们开发了诺模图来预测IV期乳腺癌患者的总体生存率。需要与国际合作进行前瞻性设计的研究,以进一步验证我们的列线图。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号